AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04249076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
Study NCT04205188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic exercises
Description: aerobic- balance -stretching and strengthening exercises
Study NCT02198482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Study NCT02198482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Study NCT02198482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02198482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Study NCT02198482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Study NCT02198482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Study NCT02198482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study NCT01656343 — intervention group
Intervention type: DRUG
Intervention: Calcineurin inhibitors (CNI)
Description: No Intervention
Study NCT01656343 — intervention group
Intervention type: DRUG
Intervention: Belatacept
Description: No Intervention
Study NCT01048307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prontosan wound irrigation solution
Description: Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~* cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
Study NCT01048307 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Prontosan wound irrigation solution
Description: Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~* cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).
Study NCT04009447 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: 6-week CBT-I therapy to help improve sleep quality
Study NCT04132830 — intervention group
Intervention type: OTHER
Intervention: In Utero HIV Exposure
Description: Born to mother who had HIV infection during pregnancy.
Study NCT04132830 — intervention group
Intervention type: OTHER
Intervention: No In Utero HIV Exposure
Description: Born to mother who did not have HIV infection during pregnancy.
Study NCT04154683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio®
Description: use of the Cellvizio® optical biopsy
Study NCT03287024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeGrow Stent System
Description: All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
Study NCT02978963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT focused on reducing intolerance of uncertainty
Study NCT01686659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Noninvasive Hemoglobin Monitoring
Description: Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin \[SpHb\] and Pleth Variability Index \[PVI\]) to the clinicians in the operating room
Study NCT01824524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
Study NCT04234399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluciclovine PET/CT using a digital PET/CT
Description: Fluciclovine is a radiotracer that will be used in conjunction with the high resolution digital Vereos PET/CT scanner.
Study NCT02055690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Tyrosine Kinase Inhibitor
Study NCT02055690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Tyrosine Kinase Inhibitor
Study NCT02055690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosbretabulin
Description: Vascular Disrupting Agent
Study NCT00860964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, calcium 900mg/d, VitD200iu/d and exercise
Study NCT00860964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate
Description: estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
Study NCT01706081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Each treatment will be 30 minutes in duration. Patients will receive two acupuncture treatments each week for six consecutive weeks. Patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation.
Study NCT01706081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wait-list
Description: For participants in the wait-list control group, follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment, following 6 weeks of acupuncture treatment and about 3 months after completion of treatment. BMI will be measured at the same timepoints.
Study NCT01907204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Oral 32mg/8d-16mg/4d-8mg/4d
Study NCT01907204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide by metered dose inhaler
Study NCT01907204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide by nebulization
Study NCT03144362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Sliding Techniques
Description: Bilateral Sliding Techniques
Study NCT03144362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral Sliding Techniques
Description: Unilateral Sliding Techniques
Study NCT00757744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
Description: once weekly individual counseling
Study NCT00757744 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drug counseling
Description: individual drug counseling
Study NCT00222430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Description: Use of fluoroscopy during arterial insertion of coronary catheter
Study NCT00222430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Standard coronary angiography technique; no fluoroscopic assistance
Study NCT03524690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Energy Balance
Description: Energy Balance Sufficient food provided to maintain energy balance.
Study NCT03524690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Negative Energy Balance
Description: Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance.
Study NCT04041466 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AF detection by ECG
Description: Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
Study NCT04256668 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Obtaining one or semen samples
Description: Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
Study NCT04256668 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Obtaining one or semen samples
Description: Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
Study NCT03315104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLU-IGIV
Description: Single dose, sterile liquid formulation for IV administration.
Study NCT01973166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond Q-switched Laser Treatment
Study NCT03315104 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for FLU-IGIV
Description: Single dose, normal saline solution for IV administration.
Study NCT01434394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Erbitux-based chemotherapy
Description: Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)
Study NCT02885454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/ethinylestradiol
Description: Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
Study NCT02885454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
Study NCT02885454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
Study NCT02885454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
Study NCT02890329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT01973166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanosecond Q-switched Laser Treatment
Study NCT01014650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13
Description: single IV or SC dose
Study NCT02890329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01696617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole 6-week group
Study NCT01696617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole 8-week group
Study NCT06605326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Treprostinil
Description: Patients in this group received subcutaneous treprostinil, starting at a dose of 1.25 to 4 ng/kg/min and gradually titrated according to patient response. The target dose was over 20 ng/kg/min after 3 months of treatment. All patients were referred for lung transplantation during or after treprostinil treatment.
Study NCT01014650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: Single IV dose of normal saline
Study NCT04404751 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Iodised salt with Iron, Folic acid and Vitamin B12
Description: Fortified salt with either Iron and Iodine only or Fortified salt with Iodine, iron, Folic acid and Vitamin B12 compared with standard Iodized salt
Study NCT04404751 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Iodised salt with Iron, Folic acid and Vitamin B12
Description: Fortified salt with either Iron and Iodine only or Fortified salt with Iodine, iron, Folic acid and Vitamin B12 compared with standard Iodized salt
Study NCT04022772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT04022772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT03967795 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: N2-L-Alanyl-L-Glutamine (Substance)
Description: 20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
Study NCT03816943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whatsapp
Description: a WhatsApp message with encouraging words will be sent after bond up
Study NCT03816943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Call
Description: a telephone call will be made after bond up to provide encoring words
Study NCT01590277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ethanol
Description: Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.
Study NCT01590277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Iomazenil
Description: Active iomazenil, administered intravenously at a dose of 3.7 ug/kg. Administered over 10 minutes, beginning 10 minutes after the start of the ethanol/placebo clamp.
Study NCT01590277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: no alcohol, administered for a total of 90 minutes.
Study NCT01590277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: no alcohol, administered for a total of 90 minutes.
Study NCT01590277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: no iomazenil, administered for a total of 10 minutes
Study NCT04022772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT04022772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04022772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01590277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: no iomazenil, administered for a total of 10 minutes
Study NCT04022772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04022772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04022772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Participate in PACK Health program
Study NCT03096093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACIT-1
Description: Cell suspension
Study NCT02923479 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Specific ankle rehabilitation by Biodex System 3 dynamometer
Description: Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer
Study NCT02923479 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Specific ankle rehabilitation by ProKin PK254 platform
Description: Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
Study NCT04288167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sample collection
Description: Samples of urine and saliva will be collected from participants using customary sample collection means.
Study NCT04288167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sample collection
Description: Samples of urine and saliva will be collected from participants using customary sample collection means.
Study NCT00459667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
Study NCT00459667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
Study NCT00459667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.~Phase B: All patients will receive 500µg s.c.every other day (open-label).
Study NCT03792308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR206
Description: SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13.
Study NCT03792308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
Study NCT02859675 — intervention group
Intervention type: OTHER
Intervention: triangular test
Description: metabolic state, impedance measurement, potential flavours evoked by sucrose,
Study NCT02859675 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: sampling of 2 mL
Study NCT04409691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednison and Sirolimus
Description: If the intravenous prednisolone 4 mg / kg / d (one time in the morning and one time in the evening, 2mg / kg body weight each time) is effective, it will be gradually reduced to 2mg / kg / D (one time in the morning and one time in the evening, 1mg / kg body weight each time), gradually converted to oral prednisone of equal dose, and the hormone will be removed within 4-6 weeks. At the same time, the dosage of sirolimus oral liquid is 0.8 mg / m2 twice a day, with an interval of 12 hours, maintaining the blood concentration of 8-15 ng / ml. if there is no intolerable side effect, the treatment will last for 6 months
Study NCT04409691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednison
Description: Prednison is taken at a dose of 4mg/kg/d. If the hormone treatment is effective, it will be gradually reduced to 2mg / kg / d (one time in the morning and one time in the evening, 1 mg / kg body weight each time), and repeated after 2 months of continuous treatment and 1 month of drug withdrawal.
Study NCT03574571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2
Description: Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
Study NCT03574571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2
Description: Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
Study NCT03574571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
Study NCT02859675 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Stunkard, PrefQuest
Study NCT01054040 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Portion plate given to cardiac rehabilitation patients
Description: Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate